{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:59:13Z","timestamp":1772110753792,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11060-025-05409-y","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:56:59Z","timestamp":1768813019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Differences in regional developmental origins of glioblastomas revealed by integrated molecular profiling"],"prefix":"10.1007","volume":"176","author":[{"given":"Ryan","family":"Gensler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Karim","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Alfonzo Horowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawad M.","family":"Khalifeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Negar","family":"Sadeghipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa","family":"Abdulrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Glantz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonikpreet","family":"Aulakh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore","family":"Nicolaides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calixto-Hope G.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivasan","family":"Yegnasubramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordina","family":"Rincon-Torroella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chetan","family":"Bettegowda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"5409_CR1","doi-asserted-by":"publisher","first-page":"105780","DOI":"10.1016\/j.phrs.2021.105780","volume":"171","author":"W Wu","year":"2021","unstructured":"Wu W et al (2021) Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol Res 171:105780","journal-title":"Pharmacol Res"},{"key":"5409_CR2","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","volume":"26","author":"M Price","year":"2024","unstructured":"Price M et al (2024) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2017\u20132021. Neuro-Oncol 26:vi1\u2013vi85","journal-title":"Neuro-Oncol"},{"key":"5409_CR3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl J Med 352:987\u2013996","journal-title":"N Engl J Med"},{"key":"5409_CR4","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R et al (2017) Effect of Tumor-Treating fields plus maintenance Temozolomide vs maintenance Temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA 318:2306\u20132316","journal-title":"JAMA"},{"key":"5409_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol (Berl) 131:803\u2013820","journal-title":"Acta Neuropathol (Berl)"},{"key":"5409_CR6","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncol 23:1231\u20131251","journal-title":"Neuro-Oncol"},{"key":"5409_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2176\/nmc.ra.2017-0010","volume":"57","author":"T Komori","year":"2017","unstructured":"Komori T (2017) The 2016 WHO classification of tumours of the central nervous system: the major points of revision. Neurol Med Chir (Tokyo) 57:301\u2013311","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"5409_CR8","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.2217\/pgs-2018-0078","volume":"19","author":"JS Young","year":"2018","unstructured":"Young JS, Prados MD (2018) Butowski, N. Using genomics to guide treatment for glioblastoma. Pharmacogenomics 19:1217\u20131229","journal-title":"Pharmacogenomics"},{"key":"5409_CR9","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-022-05425-2","volume":"611","author":"A Lomakin","year":"2022","unstructured":"Lomakin A et al (2022) Spatial genomics maps the structure, nature and evolution of cancer clones. Nature 611:594\u2013602","journal-title":"Nature"},{"key":"5409_CR10","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1093\/neuonc\/noad164","volume":"26","author":"AM Saratsis","year":"2024","unstructured":"Saratsis AM, Knowles T, Petrovic A, Nazarian J (2024) H3K27M mutant glioma: disease definition and biological underpinnings. Neuro-Oncol 26:S92\u2013S100","journal-title":"Neuro-Oncol"},{"key":"5409_CR11","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1056\/NEJMra2116344","volume":"386","author":"AR Cohen","year":"2022","unstructured":"Cohen AR (2022) Brain tumors in children. N Engl J Med 386:1922\u20131931","journal-title":"N Engl J Med"},{"key":"5409_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/jmri.26562","volume":"50","author":"H Pang","year":"2019","unstructured":"Pang H et al (2019) 3D-ASL perfusion correlates with VEGF expression and overall survival in glioma patients: comparison of quantitative perfusion and pathology on accurate Spatial location-matched basis. J Magn Reson Imaging JMRI 50:209\u2013220","journal-title":"J Magn Reson Imaging JMRI"},{"key":"5409_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ccell.2015.09.007","volume":"28","author":"SR Alcantara Llaguno","year":"2015","unstructured":"Alcantara Llaguno SR et al (2015) Adult Lineage-Restricted CNS progenitors specify distinct glioblastoma subtypes. Cancer Cell 28:429\u2013440","journal-title":"Cancer Cell"},{"key":"5409_CR14","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1038\/s41588-022-01205-w","volume":"54","author":"S Jessa","year":"2022","unstructured":"Jessa S et al (2022) K27M in canonical and noncanonical H3 variants occurs in distinct oligodendroglial cell lineages in brain midline gliomas. Nat Genet 54:1865\u20131880","journal-title":"Nat Genet"},{"key":"5409_CR15","doi-asserted-by":"publisher","first-page":"14377","DOI":"10.1038\/s41598-021-92943-0","volume":"11","author":"E Kazarian","year":"2021","unstructured":"Kazarian E et al (2021) Topographic correlates of driver mutations and endogenous gene expression in pediatric diffuse midline gliomas and hemispheric high-grade gliomas. Sci Rep 11:14377","journal-title":"Sci Rep"},{"key":"5409_CR16","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00401-017-1771-1","volume":"134","author":"M Nomura","year":"2017","unstructured":"Nomura M et al (2017) Distinct molecular profile of diffuse cerebellar gliomas. Acta Neuropathol (Berl) 134:941\u2013956","journal-title":"Acta Neuropathol (Berl)"},{"key":"5409_CR17","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1073\/pnas.1303607110","volume":"110","author":"PJ Killela","year":"2013","unstructured":"Killela PJ et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci 110:6021\u20136026","journal-title":"Proc Natl Acad Sci"},{"key":"5409_CR18","doi-asserted-by":"publisher","first-page":"709","DOI":"10.18632\/oncotarget.588","volume":"3","author":"Y Jiao","year":"2012","unstructured":"Jiao Y et al (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709\u2013722","journal-title":"Oncotarget"},{"key":"5409_CR19","doi-asserted-by":"publisher","first-page":"7090","DOI":"10.1038\/s41467-023-42752-y","volume":"14","author":"ME Rowland","year":"2023","unstructured":"Rowland ME et al (2023) Systemic and intrinsic functions of ATRX in glial cell fate and CNS myelination in male mice. Nat Commun 14:7090","journal-title":"Nat Commun"},{"key":"5409_CR20","doi-asserted-by":"publisher","first-page":"e1002772","DOI":"10.1371\/journal.pgen.1002772","volume":"8","author":"CA Lovejoy","year":"2012","unstructured":"Lovejoy CA et al (2012) Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 8:e1002772","journal-title":"PLoS Genet"},{"key":"5409_CR21","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1126\/science.1207313","volume":"333","author":"CM Heaphy","year":"2011","unstructured":"Heaphy CM et al (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Science 333:425\u2013425","journal-title":"Science"},{"key":"5409_CR22","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.3390\/brainsci11121655","volume":"11","author":"A Erira","year":"2021","unstructured":"Erira A, Velandia F, Penagos J, Zubieta C, Arboleda G (2021) Differential regulation of the EGFR\/PI3K\/AKT\/PTEN pathway between Low- and High-Grade gliomas. Brain Sci 11:1655","journal-title":"Brain Sci"},{"key":"5409_CR23","doi-asserted-by":"publisher","first-page":"dmm052005","DOI":"10.1242\/dmm.052005","volume":"17","author":"KM Ferguson","year":"2024","unstructured":"Ferguson KM et al (2024) Modelling quiescence exit of neural stem cells reveals a FOXG1-FOXO6 axis. Dis Model Mech 17:dmm052005","journal-title":"Dis Model Mech"},{"key":"5409_CR24","doi-asserted-by":"publisher","first-page":"eado1583","DOI":"10.1126\/sciadv.ado1583","volume":"10","author":"E Fredlund","year":"2024","unstructured":"Fredlund E et al (2024) MOXD1 is a lineage-specific gene and a tumor suppressor in neuroblastoma. Sci Adv 10:eado1583","journal-title":"Sci Adv"},{"key":"5409_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s00401-024-02831-w","volume":"148","author":"N Mikolajewicz","year":"2024","unstructured":"Mikolajewicz N et al (2024) Functional profiling of murine glioma models highlights targetable immune evasion phenotypes. Acta Neuropathol (Berl) 148:74","journal-title":"Acta Neuropathol (Berl)"},{"key":"5409_CR26","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1093\/neuonc\/noac110","volume":"24","author":"A Sch\u00f6nrock","year":"2022","unstructured":"Sch\u00f6nrock A et al (2022) MEOX2 homeobox gene promotes growth of malignant gliomas. Neuro-Oncol 24:1911\u20131924","journal-title":"Neuro-Oncol"},{"key":"5409_CR27","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.nbd.2009.02.017","volume":"34","author":"M Decressac","year":"2009","unstructured":"Decressac M et al (2009) Neuropeptide Y stimulates proliferation, migration and differentiation of neural precursors from the subventricular zone in adult mice. Neurobiol Dis 34:441\u2013449","journal-title":"Neurobiol Dis"},{"key":"5409_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fncel.2015.00085","volume":"9","author":"MC Geloso","year":"2015","unstructured":"Geloso MC, Corvino V, Di Maria V, Marchese E, Michetti F (2015) Cellular targets for neuropeptide Y-mediated control of adult neurogenesis. Front Cell Neurosci 9:85","journal-title":"Front Cell Neurosci"},{"key":"5409_CR29","doi-asserted-by":"publisher","first-page":"1455572","DOI":"10.3389\/fcell.2024.1455572","volume":"12","author":"P Yadav","year":"2024","unstructured":"Yadav P, Jain R, Yadav RK (2024) Emerging roles of cancer-associated histone mutations in genomic instabilities. Front Cell Dev Biol 12:1455572","journal-title":"Front Cell Dev Biol"},{"key":"5409_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s40478-019-0864-6","volume":"7","author":"K Th\u00fcmmler","year":"2019","unstructured":"Th\u00fcmmler K et al (2019) Polarizing receptor activation dissociates fibroblast growth factor 2 mediated Inhibition of myelination from its neuroprotective potential. Acta Neuropathol Commun 7:212","journal-title":"Acta Neuropathol Commun"},{"key":"5409_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/neuonc\/noy123","volume":"21","author":"HJ Cho","year":"2019","unstructured":"Cho HJ et al (2019) Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma. Neuro-Oncol 21:47\u201358","journal-title":"Neuro-Oncol"},{"key":"5409_CR32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1101\/gad.215802","volume":"16","author":"CC Stolt","year":"2002","unstructured":"Stolt CC et al (2002) Terminal differentiation of myelin-forming oligodendrocytes depends on the transcription factor Sox10. Genes Dev 16:165\u2013170","journal-title":"Genes Dev"},{"key":"5409_CR33","doi-asserted-by":"crossref","unstructured":"Pozniak CD et al (2010) Sox10 directs neural stem cells toward the oligodendrocyte lineage by decreasing Suppressor of Fused expression. Proc Natl Acad Sci USA 107:21795\u201321800","DOI":"10.1073\/pnas.1016485107"},{"key":"5409_CR34","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1038\/s41588-022-01236-3","volume":"54","author":"I Liu","year":"2022","unstructured":"Liu I et al (2022) The landscape of tumor cell States and Spatial organization in H3-K27M mutant diffuse midline glioma across age and location. Nat Genet 54:1881\u20131894","journal-title":"Nat Genet"},{"key":"5409_CR35","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s00401-024-02819-6","volume":"148","author":"K Balcomb","year":"2024","unstructured":"Balcomb K et al (2024) SMOC1 colocalizes with alzheimer\u2019s disease neuropathology and delays A\u03b2 aggregation. Acta Neuropathol (Berl) 148:72","journal-title":"Acta Neuropathol (Berl)"},{"key":"5409_CR36","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1523\/JNEUROSCI.1954-20.2021","volume":"42","author":"KH Schuster","year":"2022","unstructured":"Schuster KH et al (2022) Impaired oligodendrocyte maturation is an early feature in SCA3 disease pathogenesis. J Neurosci Off J Soc Neurosci 42:1604\u20131617","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"5409_CR37","doi-asserted-by":"publisher","first-page":"666623","DOI":"10.3389\/fmolb.2021.666623","volume":"8","author":"J Wang","year":"2021","unstructured":"Wang J et al (2021) Prognostic potential of secreted modular Calcium-Binding protein 1 in Low-Grade glioma. Front Mol Biosci 8:666623","journal-title":"Front Mol Biosci"},{"key":"5409_CR38","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.3892\/ol.2014.2013","volume":"7","author":"S Qi","year":"2014","unstructured":"Qi S et al (2014) Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett 7:1895\u20131902","journal-title":"Oncol Lett"},{"key":"5409_CR39","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel AP et al (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344:1396\u20131401","journal-title":"Science"},{"key":"5409_CR40","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.ccell.2020.04.001","volume":"37","author":"ML Suv\u00e0","year":"2020","unstructured":"Suv\u00e0 ML, Tirosh I (2020) The glioma stem cell model in the era of Single-Cell genomics. Cancer Cell 37:630\u2013636","journal-title":"Cancer Cell"},{"key":"5409_CR41","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel C et al (2019) An integrative model of cellular States, Plasticity, and genetics for glioblastoma. Cell 178:835\u2013849e21","journal-title":"Cell"},{"key":"5409_CR42","doi-asserted-by":"crossref","unstructured":"Liebelt BD et al (2016) Glioma stem cells: signaling, microenvironment, and therapy. Stem Cells Int 2016;7849890","DOI":"10.1155\/2016\/7849890"},{"key":"5409_CR43","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.trecan.2020.01.009","volume":"6","author":"BC Prager","year":"2020","unstructured":"Prager BC, Bhargava S, Mahadev V, Hubert CG, Rich JN (2020) Glioblastoma stem cells: driving resilience through chaos. Trends Cancer 6:223\u2013235","journal-title":"Trends Cancer"},{"key":"5409_CR44","doi-asserted-by":"publisher","first-page":"eaal2380","DOI":"10.1126\/science.aal2380","volume":"357","author":"WA Flavahan","year":"2017","unstructured":"Flavahan WA, Gaskell E, Bernstein BE (2017) Epigenetic plasticity and the hallmarks of cancer. Science 357:eaal2380","journal-title":"Science"},{"key":"5409_CR45","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41583-018-0014-3","volume":"19","author":"D Laug","year":"2018","unstructured":"Laug D, Glasgow SM, Deneen B (2018) A glial blueprint for gliomagenesis. Nat Rev Neurosci 19:393\u2013403","journal-title":"Nat Rev Neurosci"},{"key":"5409_CR46","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.stem.2016.11.003","volume":"20","author":"BB Liau","year":"2017","unstructured":"Liau BB et al (2017) Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance. Cell Stem Cell 20:233\u2013246e7","journal-title":"Cell Stem Cell"},{"key":"5409_CR47","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1016\/j.wneu.2013.02.010","volume":"80","author":"H Adams","year":"2013","unstructured":"Adams H et al (2013) Adult cerebellar glioblastoma: Understanding survival and prognostic factors using a population-based database from 1973 to 2009. World Neurosurg 80:e237\u2013243","journal-title":"World Neurosurg"},{"key":"5409_CR48","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jns.2007.04.003","volume":"260","author":"R Ramnarayan","year":"2007","unstructured":"Ramnarayan R, Dodd S, Das K, Heidecke V, Rainov NG (2007) Overall survival in patients with malignant glioma May be significantly longer with tumors located in deep grey matter. J Neurol Sci 260:49\u201356","journal-title":"J Neurol Sci"},{"key":"5409_CR49","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1227\/01.neu.0000430288.85680.37","volume":"73","author":"S Jeswani","year":"2013","unstructured":"Jeswani S et al (2013) Comparison of survival between cerebellar and supratentorial glioblastoma patients: surveillance, epidemiology, and end results (SEER) analysis. Neurosurgery 73:240\u2013246 discussion 246; quiz 246","journal-title":"Neurosurgery"},{"key":"5409_CR50","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/neuros\/nyx349","volume":"83","author":"Y Esquenazi","year":"2018","unstructured":"Esquenazi Y et al (2018) Thalamic glioblastoma: clinical Presentation, management Strategies, and outcomes. Neurosurgery 83:76\u201385","journal-title":"Neurosurgery"},{"key":"5409_CR51","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.medj.2024.08.010","volume":"5","author":"L Tong","year":"2024","unstructured":"Tong L et al (2024) Patient-derived organoids in precision cancer medicine. Med 5:1351\u20131377","journal-title":"Med"},{"key":"5409_CR52","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s43018-023-00595-y","volume":"4","author":"A P\u00e9rez-Gonz\u00e1lez","year":"2023","unstructured":"P\u00e9rez-Gonz\u00e1lez A, B\u00e9vant K, Blanpain C (2023) Cancer cell plasticity during tumor progression, metastasis and response to therapy. Nat Cancer 4:1063\u20131082","journal-title":"Nat Cancer"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05409-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05409-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05409-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:02:18Z","timestamp":1772107338000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05409-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["5409"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05409-y","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were carried out in accordance with relevant guidelines and regulations, including the Declaration of Helsinki and applicable U.S. regulations. This study analyzed retrospective, de-identified human molecular and clinical data. The Johns Hopkins Medicine Institutional Review Board reviewed the protocol and determined it to be exempt (IRB00486453). Informed consent was waived\/not required because the study used de-identified retrospective data and involved no direct patient contact or intervention.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"170"}}